Results 111 to 120 of about 23,901 (228)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis

, 2018
Masashi Uehara, Yukio Nakamura, Jun Takahashi, Takako Suzuki, Hiroyuki Kato Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan Background: Multiple-system atrophy (MSA) is an α-synucleinopathy with a very ...
Kato H, Suzuki T, Nakamura Y, Uehara M, Takahashi J   +4 more
core  

Evaluation of triplet therapy combined with robot‐assisted cytoreductive prostatectomy for high‐volume metastatic prostate cancer: a multicentre randomised controlled trial protocol

BJU International, Volume 138, Issue 5, Page 807-814, November 2026.
Background Prostate cancer (PCa) is the second most common cancer in men. For patients with high‐volume metastatic PCa (mPCa) who are fit for docetaxel, a triplet therapy regimen consisting of androgen deprivation therapy (ADT), chemotherapy, and an androgen receptor pathway inhibitor (ARPI) is recommended.
Xiangwei Yang, Zhuobin He, Jian Chen, Hanqi Lei, Binyuan Yan, Linze Chen, Hong Liu, Jun Pang   +7 more
wiley   +1 more source

DENOSUMAB TÜRKİYE VERİLERİ: KRONİK BÖBREK HASTALIĞI’NIN DENOSUMAB SONLANIM NOKTALARINA ETKİSİ; TÜRK ONKOLOJİ GRUBU(TOG) ÇALIŞMAS

, 2023
Amaç: Denosumab, kemik remodellingini düzenleyen önemli bir ligand olan NFkB ligandının (RANKL) reseptör aktivatörünü spesifik olarak bağlar ve inaktive eder.
Semiz, Hüseyin Salih, Alan, Özkan, Aksoy, Sercan, Yeşil Çınkır, Havva, İlhan, Yusuf, Yıldırım, Nilgün, Yavuzşen, Tuğba, Ak, Naziye, Özçelik, Melike, Turhal, Serdar, Yıldırım, Hasan Çağrı, Düzköprü, Yakup, Karaboyun, Kubilay, Türkmen Bekmez, Esra, Ellez, Halil İbrahim, Imamoğlu, Gökçen Inanç, Kuş, Fatih, Bayram, Ertuğrul, Sakalar, Teoman, Erdoğan, Atike Pınar, Ekinci, Ferhat, Karakurt Eryılmaz, Melek, Karataş, Fatih   +22 more
core   +1 more source

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience

Therapeutic Advances in Urology, 2017
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality.
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer   +3 more
doaj   +1 more source

Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68Gallium‐DOTATATE positron emission tomography

Journal of Neuroendocrinology, Volume 38, Issue 11, November 2026.
Abstract Tumors of neuroendocrine origin are a heterogenous group of related neoplasms which can arise from anywhere in the body. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status and grade (Ki‐67 expression and/or mitotic rate), with significant prognostic variability accordingly. Historically, the prevalence of
Tucker W. Coston, Himil J. Mahadevia, Marie M. Plante, Alex Hochwald, Joseph M. Accurso, Akash Sharma, Geoffrey B. Johnson, Jonathan B. Ashman, A. Tuba Kendi, Mohamad Bassam Sonbol, Patrick W. McGarrah, Timothy J. Hobday, Thorvardur R. Halfdanarson, Jason S. Starr   +13 more
wiley   +1 more source

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

, 2015
Josep Darbà,1 Lisette Kaskens,2 Francesc Sorio Vilela,3 Mickael Lothgren4 1Department of Economics, Universitat de Barcelona, 2BCN Health Economics and Outcomes Research SL, 3Amgen SA, Barcelona, Spain; 4Amgen (Europe) GmbH, Zug, Switzerland ...
Darbà J, Lothgren M, Kaskens L, Sorio Vilela F   +3 more
core  

Denosumab for the treatment of osteoporosis

, 2017
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients
Michael R. McClung
core   +1 more source

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2036-2049, October 2026.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

Denosumab: A novel antiresorptive drug for osteoporosis

, 2015
Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures.
Ernest Suresh, Bo Abrahamsen, Suresh, Ernest, Abrahamsen, Bo; id_orcid   +3 more
core   +1 more source

Exceptional Locoregional Pathological Response in Metastatic Triple‐Negative Breast Cancer Treated With Palliative Platinum‐Based Chemotherapy

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Locoregional pathological complete response with concurrent radiologic metabolic remission following palliative gemcitabine–carboplatin chemotherapy in young, low‐grade metastatic triple‐negative breast cancer patient suggests potential chemosensitivity in select advanced cases, warranting further clinical investigation.
Shristi Gupta, Abhisek Jha, Asmita Rayamajhi, Aron Neupane, Kshitiz Parajuli, Manash Jha   +5 more
wiley   +1 more source